Attis Industries Adding Volume for Commercial Labs

New Clinic and Increased Volume Expected to Provide Immediate Revenue Growth

MILTON, GA, Oct. 31, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company  emphasizing renewable fuels, bio-based plastics, healthcare and plans to build a communications infrastructure business, today announced thatit has reached an agreement with a regional medical clinic based in Oklahoma to process its blood samples through the labs that Attis Healthcare manages.  This clinic, which has multiple providers, treats patients suffering from chronic pain.  In an effort to provide the best possible patient care, this clinic will begin sending blood wellness samples through Attis effective immediately. This added volume for Attis’ commercial labs, including the lab that it manages in conjunction with Macon County Community Hospital in Lafayette, Tennessee, will help drive additional revenue for Attis’ Healthcare division.

“I’m pleased with the Healthcare team’s ability to grow our business through excellent customer service for our physician customers and their patients,” said Rob Dunn, President of the Company’s Healthcare Division. “The addition of this new clinic to our existing customer base should allow us to grow our revenue immediately, which will have a direct impact to our shareholders. We believe that an account of this size can generate upwards of $1 million dollars in annualized revenue.”  

This is the first clinic signed directly with Attis Healthcare since being notified of its receipt of its Medicare license at its federal lab in Tulsa, OK, as well as Attis’ announced partnership with NorthCrest Hospital in Springfield, Tennessee.  “Attis continues to leverage our sales expertise to build partnerships with rural hospitals while getting access to volumes with pain clinics, long term care facilities, and physician practices, including primary care physicians,” stated Dunn.    

“This is a great start for our expanding healthcare division as we continue to grow the business through direct sales efforts,” says Jeff Cosman, CEO of Attis Industries. “In addition, I am excited to announce our Attis Innovations division will soon begin promoting its technology platform through a series of video releases that will be posted on the website in the coming days and months.  The step by step videos will enable investors and interested parties to learn more about our Innovations division and our plan to cost effectively replace fossil fuels with bio-based feedstocks.  Finally, the series of videos will transition from learning about our technology to testing and validating end use products created by our process.  Updates about our healthcare and innovations business will continue to be updated on our website,”

Attis Industries Inc. 
Attis Industries, Inc. (NASDAQ: ATIS) is a holding company defined by our commitment to servicing our customers with unwavering respect, fairness and care. We are focused on finding and implementing solutions for the resource needs and challenges of our customers with a fundamental objective to seek rewarding solutions through technology and innovation. Our healthcare business centers on creating community-based synergies through collaborations and software solutions. Our innovation business strives to create value from recovered resources. For more information, visit:

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to continue to meet the listing requirements of NASDAQ; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s go-forward business, and the risks identified and discussed under the caption “Risk Factors” in the Attis Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2018 and the other documents Attis files with the SEC from time to time. There will be events in the future, however, that Attis is not able to predict accurately or control. Attis’s actual results may differ materially from the expectations that Attis describes in its forward-looking statements. Factors or events that could cause Attis’s actual results to materially differ may emerge from time to time, and it is not possible for Attis to accurately predict all of them. Any forward-looking statement made by Attis in this press release speaks only as of the date on which Attis makes it. Attis undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.